NO20083248L - Imidazoler som GABA-B reseptormodulatorer - Google Patents
Imidazoler som GABA-B reseptormodulatorerInfo
- Publication number
- NO20083248L NO20083248L NO20083248A NO20083248A NO20083248L NO 20083248 L NO20083248 L NO 20083248L NO 20083248 A NO20083248 A NO 20083248A NO 20083248 A NO20083248 A NO 20083248A NO 20083248 L NO20083248 L NO 20083248L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- alkyl
- treatment
- gaba
- imidazoles
- Prior art date
Links
- 102000017934 GABA-B receptor Human genes 0.000 title 1
- 108060003377 GABA-B receptor Proteins 0.000 title 1
- 150000002460 imidazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010021118 Hypotonia Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000036640 muscle relaxation Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0502905 | 2005-12-23 | ||
| PCT/SE2006/001463 WO2007073299A1 (en) | 2005-12-23 | 2006-12-21 | Imidazoles as gaba-b receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20083248L true NO20083248L (no) | 2008-07-23 |
Family
ID=38188930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20083248A NO20083248L (no) | 2005-12-23 | 2008-07-22 | Imidazoler som GABA-B reseptormodulatorer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080312305A1 (pt) |
| EP (1) | EP1968946A4 (pt) |
| JP (1) | JP2009521429A (pt) |
| KR (1) | KR20080090448A (pt) |
| CN (1) | CN101341131A (pt) |
| AU (1) | AU2006327316A1 (pt) |
| BR (1) | BRPI0620373A2 (pt) |
| CA (1) | CA2632020A1 (pt) |
| IL (1) | IL191767A0 (pt) |
| NO (1) | NO20083248L (pt) |
| WO (1) | WO2007073299A1 (pt) |
| ZA (1) | ZA200805160B (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401653D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
| CA2631991A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Heterocyclic gaba-b modulators |
| KR20080091452A (ko) * | 2005-12-23 | 2008-10-13 | 아스트라제네카 아베 | 위장 장애의 치료를 위한 이미다졸 유도체 |
| BRPI0620415A2 (pt) * | 2005-12-23 | 2011-11-08 | Astrazeneca Ab | composto e sais farmaceuticamente e farmacologicamente aceitáveis do mesmo, e enantiÈmeros do composto e sais do mesmo, composição farmaceutica, e, uso de um composto opcionalmente em combinação com um agonista do receptor de gabab, e, métodos para o tratamento de doença, de um distúrbio, e de sìndrome |
| CA2632021A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Gaba-b receptor modulators |
| KR101713453B1 (ko) | 2010-03-12 | 2017-03-07 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| WO2011113904A1 (en) | 2010-03-17 | 2011-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| US10653672B2 (en) | 2014-02-07 | 2020-05-19 | National University Corporation Tokyo Medical And Dental University | Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ630803A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Optically active pde10 inhibitor |
| TW201623257A (zh) | 2014-05-09 | 2016-07-01 | 奧利安公司 | 藥理活性之喹唑啉二酮衍生物 |
| KR20170139074A (ko) | 2015-04-24 | 2017-12-18 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| CA2990583A1 (en) | 2015-06-22 | 2016-12-29 | Sumitomo Dainippon Pharma Co., Ltd. | 1,4-disubstituted imidazole derivative |
| RU2018101897A (ru) * | 2015-06-22 | 2019-07-24 | Сумитомо Дайниппон Фарма Ко., Лтд. | Бициклическое гетероциклическое амидное производное |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| JP6896701B2 (ja) | 2016-02-26 | 2021-06-30 | 大日本住友製薬株式会社 | イミダゾリルアミド誘導体 |
| GB202414197D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414200D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414199D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel Compounds |
| GB202414193D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414192D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3876655A (en) * | 1971-08-18 | 1975-04-08 | Beecham Group Ltd | Anti-inflammatory acyl imidazoles |
| US4659720A (en) * | 1982-12-20 | 1987-04-21 | Merck & Co., Inc. | 5-amino or substituted amino imidazoles useful to treat coccidiosis |
| US5214063A (en) * | 1990-06-27 | 1993-05-25 | Adir Et Compagnie | 4-aminobutyric acid compounds, compositions and methods of use for treating disorders related to a dysfunction of GABAB receptors |
| FR2663934B1 (fr) * | 1990-06-27 | 1994-06-03 | Adir | Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent. |
| DE4213750A1 (de) * | 1992-04-25 | 1993-10-28 | Basf Ag | Verfahren zur Herstellung von 3-(Hydroxyphenyl)-propionaldehyden und gegebenenfalls der Herstellung von 3-(hydroxyphenyl)-propanolen |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| WO1998028313A1 (en) * | 1996-12-24 | 1998-07-02 | Novartis Ag | (thio)morpholine-substituted carboxylic and phosphinic acids |
| KR20040033048A (ko) * | 2001-09-14 | 2004-04-17 | 미츠비시 웰파마 가부시키가이샤 | 티아졸리딘 유도체 및 이의 약학적 용도 |
| SE0401653D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
| CA2632021A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Gaba-b receptor modulators |
| BRPI0620415A2 (pt) * | 2005-12-23 | 2011-11-08 | Astrazeneca Ab | composto e sais farmaceuticamente e farmacologicamente aceitáveis do mesmo, e enantiÈmeros do composto e sais do mesmo, composição farmaceutica, e, uso de um composto opcionalmente em combinação com um agonista do receptor de gabab, e, métodos para o tratamento de doença, de um distúrbio, e de sìndrome |
| KR20080091452A (ko) * | 2005-12-23 | 2008-10-13 | 아스트라제네카 아베 | 위장 장애의 치료를 위한 이미다졸 유도체 |
| CA2631991A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Heterocyclic gaba-b modulators |
| US20080262064A1 (en) * | 2007-04-18 | 2008-10-23 | Astrazeneca Ab | Novel Compounds For The Treatment Of GI Disorders 682 |
| CA2682301A1 (en) * | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | Xanthine compounds having a positive allosteric gabab receptor modulator effect |
-
2006
- 2006-12-21 WO PCT/SE2006/001463 patent/WO2007073299A1/en not_active Ceased
- 2006-12-21 KR KR1020087017999A patent/KR20080090448A/ko not_active Withdrawn
- 2006-12-21 EP EP06824533A patent/EP1968946A4/en not_active Withdrawn
- 2006-12-21 BR BRPI0620373-6A patent/BRPI0620373A2/pt not_active IP Right Cessation
- 2006-12-21 AU AU2006327316A patent/AU2006327316A1/en not_active Abandoned
- 2006-12-21 CA CA002632020A patent/CA2632020A1/en not_active Abandoned
- 2006-12-21 US US12/158,159 patent/US20080312305A1/en not_active Abandoned
- 2006-12-21 CN CNA2006800484624A patent/CN101341131A/zh active Pending
- 2006-12-21 JP JP2008547166A patent/JP2009521429A/ja active Pending
-
2008
- 2008-05-27 IL IL191767A patent/IL191767A0/en unknown
- 2008-06-12 ZA ZA200805160A patent/ZA200805160B/xx unknown
- 2008-07-22 NO NO20083248A patent/NO20083248L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20080312305A1 (en) | 2008-12-18 |
| KR20080090448A (ko) | 2008-10-08 |
| ZA200805160B (en) | 2009-10-28 |
| IL191767A0 (en) | 2008-12-29 |
| JP2009521429A (ja) | 2009-06-04 |
| WO2007073299A1 (en) | 2007-06-28 |
| CA2632020A1 (en) | 2007-06-28 |
| AU2006327316A1 (en) | 2007-06-28 |
| EP1968946A1 (en) | 2008-09-17 |
| CN101341131A (zh) | 2009-01-07 |
| BRPI0620373A2 (pt) | 2011-11-08 |
| EP1968946A4 (en) | 2010-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20083248L (no) | Imidazoler som GABA-B reseptormodulatorer | |
| NO20083247L (no) | GABA-B reseptormodulatorer | |
| NO20083243L (no) | Pyrazoler for behandling av GERD og IBS | |
| NO20083249L (no) | Imidazolderivater for behandling av gastrointestinale forstyrrelser | |
| NO20083244L (no) | Heterosykliske GABA-B modulatorer | |
| EA201101334A1 (ru) | Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их | |
| EA200870489A1 (ru) | Пиперидинилзамещённые пирролидиноны в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы 1 | |
| NO20083057L (no) | Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer | |
| SMT201300085B (it) | Composti di pirrolo | |
| DK2021337T3 (da) | Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1 | |
| UA95454C2 (uk) | Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну | |
| NO20085140L (no) | Nye indazolderivater som har spiro ringstruktur i sidekjede | |
| DK2029529T3 (da) | Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1 | |
| EA200970612A1 (ru) | Производные индола в качестве агонистов рецептора s1p1 | |
| EA200971044A1 (ru) | Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| EA201001647A1 (ru) | Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов | |
| EA201070039A1 (ru) | Спироциклы в качестве ингибиторов 11-бета гидроксилстероиддегидрогеназы типа 1 | |
| PE20091425A1 (es) | Derivados de aminotiazol | |
| EA200901098A1 (ru) | Производные тиазола в качестве модуляторов сопряженных с g-белком рецепторов | |
| MX2010001170A (es) | Derivados de imidazolona, metodo de preparacion de los mismos y uso biologico de los mismos. | |
| NO20076478L (no) | Substituerte oksadiazolderivater som positive allosteriske modulatorer av metabotrope glutamatreseptorer | |
| HN2011001606A (es) | Antagonistas de 4-azetidinil -1-heteroaril -ciclohexanol de ccr2 | |
| AR072242A1 (es) | Derivados de imidazopiridina, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neuromusculares. | |
| WO2010003084A3 (en) | Phosphodiesterase 4 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |